Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
暂无分享,去创建一个
Udo Greiser | C. Mamot | John W. Park | J. Marks | U. Greiser | D. Drummond | D. Kirpotin | K. Hong | James D Marks | Daryl C Drummond | Keelung Hong | John W Park | Dmitri B Kirpotin | Christoph Mamot
[1] U. Nielsen,et al. Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[2] John W. Park,et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[3] F. Szoka,et al. Comparative properties and methods of preparation of lipid vesicles (liposomes). , 1980, Annual review of biophysics and bioengineering.
[4] S. Spencer,et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Mendelsohn. The epidermal growth factor receptor as a target for cancer therapy. , 2001, Endocrine-Related Cancer.
[6] A. Antony,et al. The biological chemistry of folate receptors. , 1992, Blood.
[7] E. Claassen,et al. Post-formation fluorescent labelling of liposomal membranes. In vivo detection, localisation and kinetics. , 1992, Journal of immunological methods.
[8] C. James,et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[9] J. Marks,et al. Phage libraries--a new route to clinically useful antibodies. , 1996, The New England journal of medicine.
[10] D. Bigner,et al. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system , 2002, Cancer Immunology, Immunotherapy.
[11] J. Swanson,et al. Macrophages possess probenecid-inhibitable organic anion transporters that remove fluorescent dyes from the cytoplasmic matrix , 1987, The Journal of cell biology.
[12] G. Carpenter,et al. Epidermal growth factor-receptor-protein kinase interactions. , 1981, Progress in clinical and biological research.
[13] Ulrik B Nielsen,et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] N. Goldstein,et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] Y. Barenholz,et al. Gelation of liposome interior A novel method for drug encapsulation , 1992, FEBS letters.
[16] P. Humphrey,et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[17] G. R. Bartlett. Phosphorus assay in column chromatography. , 1959, The Journal of biological chemistry.
[18] Y. Barenholz,et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.
[19] N. Van Rooijen,et al. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. , 1994, Biochimica et biophysica acta.
[20] D. Papahadjopoulos,et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.
[21] J. Mendelsohn,et al. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. , 1993, Cancer research.
[22] C. Osborne,et al. Targeting the EGF receptor in breast cancer treatment , 2004, Breast Cancer Research and Treatment.
[23] Ulrik B Nielsen,et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. , 2002, Biochimica et biophysica acta.
[24] M. Shibuya,et al. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors , 1988, Molecular and cellular biology.
[25] Y. Kan,et al. Antibodies to human fetal erythroid cells from a nonimmune phage antibody library , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[26] R. McLendon,et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. , 1995, Cancer research.
[27] P. Humphrey,et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. , 1988, Cancer research.
[28] D. Papahadjopoulos,et al. Endocytosis and intracellular fate of liposomes using pyranine as a probe. , 1990, Biochemistry.
[29] John W. Park,et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.
[30] J. Gerhart,et al. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[31] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[32] L. Norton,et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Mendelsohn,et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. , 1983, Molecular biology & medicine.
[34] M. Shibuya,et al. A Deletion Mutation within the Ligand Binding Domain Is Responsible for Activation of Epidermal Growth Factor Receptor Gene in Human Brain Tumors , 1990, Japanese journal of cancer research : Gann.
[35] T. Allen,et al. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. , 2001, Biochimica et biophysica acta.
[36] D. B. Evans,et al. Immunodetection of recombinant proteins based on antibodies directed against a metal binding peptide engineered for purification by immobilized metal affinity chromatography. , 1992, Journal of immunological methods.
[37] R. McLendon,et al. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. , 1997, Cancer research.
[38] D. Scudiero,et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. , 1988, Cancer research.
[39] F. Chang,et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] John W. Park,et al. Immunoliposomes for cancer treatment. , 1997, Advances in pharmacology.